Drugs / Zenagamtide
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07868354 | Oct 2026 → Sep 2028 expected | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07855133 | Sep 2026 → Sep 2028 expected | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07815067 | Sep 2026 → Jun 2028 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT07668401 | Jan 2027 → Jan 2029 expected | obesity disorder | Novo Nordisk A/S | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07861100 | Oct 2026 → Sep 2030 expected | obesity disorder | Novo Nordisk A/S | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07668414 | Sep 2026 → Oct 2028 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 3 | NCT07720271 | Aug 2026 → Jun 2028 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 3 | NCT07797335 | Aug 2026 → Jul 2028 expected | type 2 diabetes mellitus | Novo Nordisk A/S | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-06-05 | Novo Nordisk A/S | Results Novo Nordisk’s investigational zenagamtide shows significant HbA1C reductions with up to 14.6% weight loss in adults with type 2 diabetes - presented at ADA 2026 novonordisk.com ↗
A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to placebo, with up to 89.1% achieving HbA1C below 7%1 |
All press releases naming this drug 2 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zenagamtide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07861100 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT07668401 ↗ |